logo
Share SHARE
FONT-SIZE Plus   Neg

BioCryst Reveals Favorable Results From Ulodesine In Phase II Clinical Trials

BioCryst Pharmaceuticals Inc (BCRX: Quote) Tuesday released positive results from the extension phase of its randomized Phase 2b trial of ulodesine added to allopurinol in patients with gout, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.

The pharmaceutical company engaged in the design, optimization and development of novel small molecule drugs, revealed that the results of the 52-week, blinded Phase 2b safety extension trial confirm that ulodesine continues to be generally safe and well-tolerated in gout patients who inadequately responded to allopurinol alone, many of which had multiple co-morbidities. No clinical adverse event signals were observed that distinguished ulodesine from placebo, either by type or by rate at the doses tested.

Ulodesine is a novel enzyme inhibitor with the potential for once-a-day oral dosing suitable for chronic administration to treat gout. It acts upstream of xanthine oxidase (XO) in the purine metabolism pathway to reduce new formation of uric acid in patients with gout.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
While building a strong relationship with your customers is a key step in building any successful business, it is always hard (and often expensive) for a company to try to make amends when something goes wrong. Here is a list of 4 recent corporate apologies (most with refunds included). Social networking giant Facebook, Inc. said Wednesday after the markets closed that its fourth quarter profit rose 34% from last year, as revenue surged amid strong growth in mobile advertising. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly revenue. France is reported to be considering new laws that will make Internet companies like Google and Facebook liable for social media posts inciting terrorism.
comments powered by Disqus
Follow RTT